Increased cerebrospinal fluid levels of neurofilament protein in progressive supranuclear palsy and multiple-system atrophy compared with Parkinson's disease

Movement Disorders

Volumn 13, Issue 1, 1998, Pages 70-77

  Holmberg, Björn ^a   Rosengren, Lars ^a   Karlsson, Jan Erik ^a,b   Johnels, Bo ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Cerebrospinal fluid; Glial fibrillary acidic protein; Multiple system atrophy; Neurofilament protein; Parkinson's disease; Progressive supranuclear palsy

Indexed keywords

GLIAL FIBRILLARY ACIDIC PROTEIN; NEUROFILAMENT PROTEIN;

ADULT; AGED; ARTICLE; ASTROCYTE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DIFFERENTIAL DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; NERVE FIBER; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; PROTEIN CEREBROSPINAL FLUID LEVEL; PYRAMIDAL TRACT; SHY DRAGER SYNDROME;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; GLIAL FIBRILLARY ACIDIC PROTEIN; HUMANS; MALE; MIDDLE AGED; MULTIPLE SYSTEM ATROPHY; NEUROFILAMENT PROTEINS; PARKINSON DISEASE; PROGNOSIS; SENSITIVITY AND SPECIFICITY; STATISTICS, NONPARAMETRIC; SUPRANUCLEAR PALSY, PROGRESSIVE;

EID: 0031965346     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.870130116     Document Type: Article

References (34)

1. Gearing M, Olson D, Watts L, Mirra S. Progressive supranuclear palsy: neuropathologic and clinical heterogeneity. Neurology 1994;44:1015-1024.
2. Wenning GK. Olivopontocerebellar atrophy. Mov Disord 1996;11:157-162.
3. Wenning GK, Quinn N, Magalhaes C, Mathias C, Daniel SE. 'Minimal change' multiple system atrophy. Mov Disord 1994;9:161-166.
4. Golbe L, Davis P. Progressive supranuclear palsy. In: Jankovic J, Tolosa E, eds. Parkinson's disease and movement disorders. Baltimore, MD: Williams and Wilkins, 1993:145-161.
5. Quinn N. Multiple system atrophy: the nature of the beast. J Neurol Neurosurg Psychiatry 1989;52(spec suppl):78-89.
6. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic parkinsonism: a clinico-pathotogical study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-184.
7. Hughes AJ, Daniel SE, Kilford L, Lees AJ. A clinicopathologic study of 100 cases of Parkinson's disease. Arch Neurol 1993;50:140-148.
8. Rajput AH, Rozdilsky B, Rajput A. Accuracy of clinical diagnoses in parkinsonism: a prospective study. Can J Neurol Sci 1991;18:275-278.
9. 18F-fluorodeoxyglucose and positron emission tomography. Neurology 1995;45:1995-2004.
10. Sawle GV. The detection of preclinical Parkinson's disease: what is the role of positron emission tomography? Mov Disord 1993;8:271-277.
11. 123IBZM-SPECT. J Neurol Neurosurg Psychiatry 1994;57:1047-1056.
12. Pramstaller PP, Wenning GK, Smith SJ, Beck RO, Quinn NP, Fowler CJ. Nerve conduction studies, skeletal muscle EMG, and sphincter EMG in multiple system atrophy. J Neurol Neurosurg Psychiatry 1995;58:618-621.
13. Eardley I, Quinn NP, Fowler CJ, et al. The value of urethral sphincter electromyography in the differential diagnosis of parkinsonism. Br J Urol 1989;64:360-362.
14. Mathias CJ. Disorders affecting autonomic function in parkinsonian patients. Adv Neurol 1996;69:383-391.
15. Konagaya M, Konagaya Y, Iida M. Clinical and magnetic resonance imaging study of extrapyramidal symptoms in multiple system atrophy. J Neurol Neurosurg Psychiatry 1994;57:1528-1531.
16. Eitvan I, Agid Y, Calne D, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP International Workshop. Neurology 1996;47:1-9.
17. Rosengren LE, Wikkelsö C, Hagberg L. A sensitive ELISA for glial fibrillary acidic protein: application in CSF of adults. J Neurosci Methods 1994;51:197-204.
18. Lasec RJ. Studying the intrinsic determinants of neuronal form and function. In: Lasec RJ, Black MM, eds. Intrinsic determinants of neuronal form and function. New York: Alan R Liss, 1988:1-60.
19. Karlsson J-E, Rosengren LE, Haglid KG. Quantitative and qualitative alterations of neuronal and glial intermediate filaments in rat nervous system after exposure to 2,5-hexenedione. J Neurochem 1991;57:1437-1444.
20. Wang S, Lees GJ, Rosengren LE, et al. The effect of an N-methyl-D-aspartate lesion in the hippocampus on glial and neuronal marker proteins. Brain Res 1991;17:1005-1009.
21. Rosengren LE, Karlsson JE, Persson L, Karlsson JO, Wikkelsö C. Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament protein in CSF. J Neurochem 1996;67:2013-2020.
22. Bignami A, Dahl D. The astroglial response to stabbing: immunofluorescence studies with antibodies to astrocyte-specific protein (GFA) in mammalian and submammalian vertebrates. Neuropathol Appl Neurobiol 1976;2:99-110.
23. Rueger DC, Huston JS, Dahl D, Binami A. Formation of 100Å filaments from purified glial fibrillary acidic protein in vitro. J Mol Biol 1979;135:53-68.
24. Duchen LW. General pathology of neurons and neuroglia. In: Adams JH, Corsellis JAN, Duchen LW, eds. Greenfield's neuropathology, 4th ed. London: Edward Arnold, 1984:1-52.
25. Aurell A, Rosengren LE, Olsson J-E, Zbornikova V, Haglid KG. Determination of S-100 and GFA protein concentrations in cerebrospinal fluid after brain infarction. Stroke 1991;22:1254-1258.
26. Noppe M, Crols R, Andries D, Lowental A. Determination in human cerebrospinal fluid of non-specific or specific central nervous tissue pathology. Clin Chim Acta 1986;155:143-150.
27. Blennow M, Hagberg H, Rosengren LE. Glial fibrillary acidic protein in the cerebrospinal fluid: a possible indicator of prognosis in full-term asphyxiated newborn infants? Pediatr Res 1995;37:260-264.
28. Wallin A, Blennow K, Rosengren LE. Glial fibrillary acidic protein in the cerebrospinal fluid of patients with dementia. Dementia 1996;7:267-272.
29. Rosengren LE, Lycke J, Andersen O. Glial fibrillary acidic protein in CSF of multiple sclerosis patients: relation to neurological deficit. J Neurol Sci 1995;133:61-65.
30. Ehlers S, Kyllerman M, Rosengren LE. Analysis of glial fibrillary acidic protein in the cerebrospinal fluid of children investigated for encephalopathy. Neuropediatrics 1994;25:129-133.
31. Dotevall L, Rosengren LE, Hagberg L. Increased cerebrospinal levels of glial fibrillary acidic protein (GFAP) in Lyme neuroborreliosis. Infection 1996;24:125-129.
32. Hurtig H. Vascular parkinsonism. In: Parkinsonian syndromes. New York: Marcel Dekker, 1993:81-93.
33. Wenning GK, Ben Shlomo Y, Magalhaes, Daniel SE, Quinn NP. Clinical features and natural history of multiple system atrophy: an analysis of 100 cases. Brain 1994;117:835-845.
34. Sobue G, Hashizume Y, Mitsuma T, Takahashi A. Size-dependent myelinated fiber loss in the corticospinal tract in Shy-Drager syndrome and amyotrophic lateral sclerosis. Neurology 1987;37:529-532.